Education
About Us
Working with TipRanks
Follow Us
Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
CRNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$24.10 - $62.53
Previous CloseN/A
Volume214.21K
Average Volume (3M)683.30K
Market Cap
$2.98B
Enterprise Value$2.94B
Total Cash (Recent Filing)$1.27B
Total Debt (Recent Filing)$50.82M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Aug 07, 2025EPS Estimate
-1.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding93,680,130
10 Day Avg. Volume766,244
30 Day Avg. Volume683,302
Financial Highlights & Ratios
PEG Ratio3.02
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio-11.14
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue695.73
Enterprise Value/Gross Profit419.73K
Enterprise Value/Ebitda-2.28
Forecast
1Y Price Target
$72.50Price Target Upside127.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Crinetics Pharmaceuticals News
See All CRNX News
Bulls Say, Bears Say
Bulls Say
Commercial LaunchThe potential launch of paltusotine in acromegaly could transform the company into a commercial organization.
Pipeline DevelopmentExcitement about the emerging pipeline, including TSH antagonist in Graves' disease and TED, SST3 agonist in polycystic kidney disease, and oral GLP-1 and GIP in obesity, suggests potential to generate value.
Regulatory ConfidenceThe PDUFA date for paltusotine remains on track with routine FDA interactions, highlighting confidence in the regulatory process.
Bears Say
Investor PerceptionThere is disagreement with the notion that there is a news vacuum, with a commercial launch only a few months away and an earlier-stage pipeline that is heating up.
Safety ConcernsThere seems to be a significant investor disconnect, stemming from safety concerns with atumelnant in congenital adrenal hyperplasia and a perceived catalyst desert in the future.
Ownership Overview
2.09% Insiders
40.85% Mutual Funds
0.05% Other Institutional Investors
40.29% Public Companies and Individual Investors
CRNX FAQ
What was Crinetics Pharmaceuticals’s price range in the past 12 months?
Crinetics Pharmaceuticals lowest stock price was $24.10 and its highest was $62.53 in the past 12 months.
What is Crinetics Pharmaceuticals’s market cap?
Crinetics Pharmaceuticals’s market cap is $2.98B.
When is Crinetics Pharmaceuticals’s upcoming earnings report date?
Crinetics Pharmaceuticals’s upcoming earnings report date is Aug 07, 2025 which is in 20 days.
How were Crinetics Pharmaceuticals’s earnings last quarter?
Crinetics Pharmaceuticals released its earnings results on May 08, 2025. The company reported -$1.04 earnings per share for the quarter, missing the consensus estimate of -$0.941 by -$0.099.
Is Crinetics Pharmaceuticals overvalued?
According to Wall Street analysts Crinetics Pharmaceuticals’s price is currently Undervalued.
Does Crinetics Pharmaceuticals pay dividends?
Crinetics Pharmaceuticals does not currently pay dividends.
What is Crinetics Pharmaceuticals’s EPS estimate?
Crinetics Pharmaceuticals’s EPS estimate is -1.08.
How many shares outstanding does Crinetics Pharmaceuticals have?
Crinetics Pharmaceuticals has 93,680,130 shares outstanding.
What happened to Crinetics Pharmaceuticals’s price movement after its last earnings report?
Crinetics Pharmaceuticals reported an EPS of -$1.04 in its last earnings report, missing expectations of -$0.941. Following the earnings report the stock price went down -6.177%.
Which hedge fund is a major shareholder of Crinetics Pharmaceuticals?
Currently, no hedge funds are holding shares in CRNX
Crinetics Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$72.50 (127.27% Upside)
$72.50 (127.27% Upside)
Blogger Sentiment
Bullish
CRNX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 494.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.4%
Last 30 Days ▲ 5.8%
Last 30 Days ▲ 5.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.97%
12-Months-Change
Fundamentals
Return on Equity
-30.84%
Trailing 12-Months
Asset Growth
39.17%
Trailing 12-Months
Company Description
Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
CRNX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Crinetics Pharmaceuticals, Inc. with significant progress in regulatory approvals, strong financial positioning, and preparations for the commercial launch of paltusotine. However, the decrease in revenue and increase in operating expenses present challenges.Read More>CRNX Stock 12 Month Forecast
Average Price Target
$72.50
▲(127.27%Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Viking Therapeutics
―
Apellis Pharmaceuticals
―
Scholar Rock Holding
―
Immunovant
―